There are over 8 billion people on this planet, and for most prominent organizations with global reach, diverse representation continues to remain a challenge. In the face of seemingly obvious solutions, the question persists: why? For the healthcare landscape, the need is especially urgent—because while other industries may be able to get away with unfulfilled quotas, life sciences is rooted in keeping people alive. It is the distinct feature separating our market from the rest. And if the treatments developed in the clinical trial space do not work on all people, then how truly effective—and safe—are they? A population treated and a population left untreated still leaves the whole world vulnerable. Medidata's Kelly McKee and Rachel Horovitz, our in-house patient engagement experts, explain the core principles behind our resolute pursuit of diversity and inclusion in clinical trials, its practical benefits, and most importantly, the real steps all involved parties can take to infuse diversity into every stage of the clinical research process. Medidata is committed to innovating at the forefront of diversity initiatives in the clinical trial technology sector, and we hope our drive extends across the healthcare sphere. Connect with Medidata: LinkedIn: https://mdso.io/s7r Instagram: https://mdso.io/rng X: https://mdso.io/8du Contact us: https://www.medidata.com/en/contact-us

 207      1